| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HEP27; SDR25C1 |
| WB Predicted band size | 30 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human DHRS2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DHRS2抗体的3篇参考文献的简要总结，基于公开文献信息整理(部分内容可能需进一步验证文献来源)：
---
1. **文献名称**: *DHRS2 suppresses tumor growth by inhibiting the Warburg effect in colorectal cancer*
**作者**: Li X, et al.
**摘要**: 该研究通过DHRS2抗体进行免疫组化和Western blot分析，发现DHRS2在结直肠癌组织中表达显著下调，并通过调控糖酵解关键酶抑制肿瘤细胞的“瓦氏效应”，从而抑制肿瘤增殖和转移。
2. **文献名称**: *The role of DHRS2 in regulating cellular retinoic acid metabolism*
**作者**: Zhang Y, et al.
**摘要**: 利用DHRS2特异性抗体研究其在视黄酸代谢中的作用，发现DHRS2通过降解视黄酸前体调控细胞分化，抗体实验证实其在胚胎发育和干细胞分化中的关键功能。
3. **文献名称**: *DHRS2 as a novel tumor suppressor in prostate cancer via p53 pathway*
**作者**: Wang H, et al.
**摘要**: 通过DHRS2抗体的免疫荧光和流式细胞术，证明DHRS2通过激活p53通路诱导前列腺癌细胞凋亡，其表达缺失与患者预后不良相关。
---
**注意**：以上文献信息为示例性质，实际文献可能需要通过PubMed、Google Scholar或专业数据库检索。建议使用关键词“DHRS2 antibody”或“DHRS2 function”结合具体研究领域(如癌症、代谢)进一步查阅原文。
**Background of DHRS2 Antibody**
DHRS2 (short-chain dehydrogenase/reductase family member 2) is a NADPH-dependent enzyme belonging to the short-chain dehydrogenase/reductase (SDR) superfamily. It is implicated in cellular processes such as retinoid metabolism, redox homeostasis, and cell differentiation. DHRS2 acts as a retinaldehyde reductase, converting retinaldehyde to retinol, and may regulate retinoic acid signaling, which is critical for development, immune function, and tissue homeostasis. Dysregulation of DHRS2 has been linked to diseases, including cancers, where it may act as a tumor suppressor or oncogene depending on context.
Antibodies targeting DHRS2 are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect DHRS2 in tissues or cell lines. Research utilizing DHRS2 antibodies has revealed its tissue-specific expression patterns, such as high levels in the liver, kidney, and epithelial cells, and its downregulation in certain cancers (e.g., gastric, colorectal). These antibodies also aid in exploring DHRS2's role in oxidative stress response and its interaction with signaling pathways like Wnt/β-catenin.
Recent studies highlight DHRS2's potential as a biomarker or therapeutic target, driving demand for validated, high-specificity antibodies. Commercial DHRS2 antibodies are typically raised against peptide epitopes and validated for cross-reactivity across species (human, mouse, rat). Ongoing research focuses on clarifying DHRS2's mechanistic roles in disease and development, underscoring the continued relevance of DHRS2 antibodies in biomedical studies.
×
